Shock for EU devices industry as it hits new culture of central regulatory fees
This article was originally published in Clinica
Executive Summary
The cost to manufacturers of human tissue engineered products (hTEPs) of meeting the EU's proposed new advanced therapy products (ATP) Regulation appears astronomical to those used to the costs associated with compliance with the medical device directives.